B-ALL

(redirected from B-cell Acute Lymphoblastic Leukemia)
AcronymDefinition
B-ALLB-cell Acute Lymphoblastic Leukemia
B-ALLB-Lineage Acute Lymphoblastic Leukaemia (hematology)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/ refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Launched in the UK in August 2016, CALM is an open label, dose-escalation study designed to evaluate safety, tolerability and antileukemic activity of UCART19 in patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, acute promyelocyte leukemia; B- ALL, B-cell acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia.
BioCryst also plans to initiate a Phase I/II trial in B-cell acute lymphoblastic leukemia during the first half of 2005.
The positive opinion includes two B-cell malignancies: B-cell acute lymphoblastic leukemia that is refractory, in relapse post-transplant or in second or later relapse in patients up to 25 years of age; and diffuse large B-cell lymphoma that is relapsed or refractory after two or more lines of systemic therapy in adults.
The CALM study is an open label, dose-escalation study designed to evaluate safety, tolerability and antileukemic activity of UCART19 in adult patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia.
In addition, the European Medicines Agency has granted accelerated assessment to the Marketing Authorization Application for Kymriah for the treatment of children and young adults with r/r B-cell acute lymphoblastic leukemia, or ALL, and for adult patients with r/r DLBCL who are ineligible for ASCT.
27 June 2014 - US genomic immune profiling specialist Adaptive Biotechnologies Corp reported Friday study data showing that its clonoSEQ assay had better accuracy and sensitivity in detecting risk of relapse in patients with B-cell acute lymphoblastic leukemia (B-ALL), versus the current standard of care lab test.